Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2017, Article ID 3972706, 8 pages
Research Article

High Prevalence of Metabolic Syndrome in Patients with Discoid Lupus Erythematosus: A Cross-Sectional, Case-Control Study

Department of Dermatology, Dokuz Eylul University, Faculty of Medicine, Izmir, Turkey

Correspondence should be addressed to Ozlem Ozbagcivan; rt.ude.ued@navicgabzo.melzo

Received 23 September 2016; Accepted 7 December 2016; Published 3 January 2017

Academic Editor: Margarete D. Bagatini

Copyright © 2017 Sevgi Akarsu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Although it is known that systemic form of lupus erythematosus (LE) and metabolic syndrome (MetS) are frequently observed together, there are no published reports on MetS in patients with skin-restricted LE. We aimed to compare the frequencies of MetS and its components in discoid LE (DLE) with the non-DLE control group. Additionally, we intended to determine the differences of sociodemographic and clinical data of the DLE patients with MetS compared to the patients without MetS. This was a cross-sectional, case-control study, including 60 patients with DLE and 82 age- and gender-matched control subjects. In DLE group, the presence of MetS was observed as more frequent (48.3% versus 24.4%, ), and hypertriglyceridemia (43.3% versus 22.0%, ) and reduced HDL-cholesterol (61.7% versus 23.2%, ) among the MetS components were found significantly higher when compared to the control group. DLE patients with MetS were at older age ( versus , ), and hypertension, hyperlipidemia/dyslipidemia, and cardiovascular disease histories were observed at a higher ratio when compared to the patients without MetS. Between the DLE patients with and without MetS, no significant difference was observed in terms of clinical characteristics of DLE. Moreover, further large case-control studies with follow-up periods would be required to clearly assess the impact of MetS on the clinical outcomes of DLE.